688185 康希诺
已收盘 08-21 15:00:00
资讯
新帖
简况
康希诺：持续规划mRNA治疗性疫苗其他管线
证券之星 · 18:15
康希诺：持续规划mRNA治疗性疫苗其他管线
康希诺：定期报告截止日及其后的股东人数披露，不早于当期定期报告的披露
证券之星 · 18:15
康希诺：定期报告截止日及其后的股东人数披露，不早于当期定期报告的披露
康希诺：公司早年曾就肺炎球菌结合疫苗（PCV）的相关技术与科兴控股订立一系列协议
证券之星 · 18:15
康希诺：公司早年曾就肺炎球菌结合疫苗（PCV）的相关技术与科兴控股订立一系列协议
康希诺：横纹肌肉瘤疫苗已获批IIT
证券之星 · 18:04
康希诺：横纹肌肉瘤疫苗已获批IIT
异动快报：康希诺（688185）8月21日10点46分触及涨停板
证券之星 · 10:50
异动快报：康希诺（688185）8月21日10点46分触及涨停板
康希诺最新公告：吸附破伤风疫苗获得药品注册证书
证券之星 · 08-20 18:31
康希诺最新公告：吸附破伤风疫苗获得药品注册证书
生物疫苗股全线大涨，康希诺等5股20CM涨停，默沙东莫德纳黑色素瘤疫苗临床试验传捷报
格隆汇 · 08-20 09:47
生物疫苗股全线大涨，康希诺等5股20CM涨停，默沙东莫德纳黑色素瘤疫苗临床试验传捷报
四大指数集体高开！生物医药板块大爆发，康希诺、沃森生物一字20CM涨停，农业、煤炭板块下跌｜开盘播报
每日经济新闻 · 08-20 09:38
四大指数集体高开！生物医药板块大爆发，康希诺、沃森生物一字20CM涨停，农业、煤炭板块下跌｜开盘播报
破发股康希诺跌3.45% 2020年上市募52亿元中信证券保荐
中金财经 · 08-18
破发股康希诺跌3.45% 2020年上市募52亿元中信证券保荐
股市必读：康希诺新发布《康希诺H股公告》
证券之星 · 08-17
股市必读：康希诺新发布《康希诺H股公告》
康希诺：青少年及成人用百白破疫苗药品注册申请获受理
每日经济新闻 · 08-16
康希诺：青少年及成人用百白破疫苗药品注册申请获受理
每周股票复盘：康希诺（688185）将审议中期业绩及股息
证券之星 · 08-16
每周股票复盘：康希诺（688185）将审议中期业绩及股息
康希诺（688185）披露2026年中期业绩审议安排，8月14日股价下跌0.76%
证券之星 · 08-14
康希诺（688185）披露2026年中期业绩审议安排，8月14日股价下跌0.76%
生物制品概念强势拉升，康希诺婴幼儿百白破联合疫苗正式启动市场供应丨异动情报
南方财经网 · 08-13
生物制品概念强势拉升，康希诺婴幼儿百白破联合疫苗正式启动市场供应丨异动情报
每周股票复盘：康希诺（688185）H股及A股股本无变动
证券之星 · 08-09
每周股票复盘：康希诺（688185）H股及A股股本无变动
股市必读：康希诺新发布《康希诺H股公告》
证券之星 · 08-06
股市必读：康希诺新发布《康希诺H股公告》
每周股票复盘：康希诺（688185）脑膜炎疫苗拟扩龄至17岁
证券之星 · 07-26
每周股票复盘：康希诺（688185）脑膜炎疫苗拟扩龄至17岁
康希诺(688185.SH)：ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)药品补充申请获受理
智通财经 · 07-19
康希诺(688185.SH)：ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)药品补充申请获受理
7月17日康希诺跌6.42%，广发科创板两年定开混合基金重仓该股
证券之星 · 07-17
7月17日康希诺跌6.42%，广发科创板两年定开混合基金重仓该股
每周股票复盘：康希诺（688185）H股及A股股本无变动
证券之星 · 07-05
每周股票复盘：康希诺（688185）H股及A股股本无变动
加载更多
公司概况
公司名称：
康希诺生物股份公司
所属行业：
医药制造业
上市日期：
2020-08-13
主营业务：
康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是疫苗销售、药品生产工艺研究开发业务、技术转移及中间品销售。公司自主研发的“多糖蛋白结合疫苗关键技术及产业化”项目荣获天津市科学技术进步一等奖。
发行价格：
209.71
{"stockData":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":77.32,"timestamp":1787295600000,"preClose":64.43,"halted":0,"volume":25593388,"delay":0,"changeRate":0.2001,"floatShares":113999999,"shares":247000000,"eps":-0.0041,"marketStatus":"已收盘","change":12.89,"latestTime":"08-21 15:00:00","open":70.06,"high":77.32,"low":67.5,"amount":1891000000,"amplitude":0.1524,"askPrice":77.32,"askSize":577,"bidPrice":77.31,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-0.0041,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":5,"adr":0,"adjPreClose":64.43,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787275800000,1787283000000],[1787288400000,1787295600000]],"highLimit":70.87,"lowLimit":57.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":247043801,"isCdr":false,"pbRate":3.88,"roa":"--","roe":"--","epsLYR":0.11,"committee":-0.387019,"marketValue":19101000000,"turnoverRate":0.2238,"status":0,"afterMarket":{"amount":231960,"volume":3000,"close":77.32,"buyVolume":1917,"sellVolume":0,"time":1787297637746,"indexStatus":"已收盘 08-21 15:30:00","preClose":64.43},"hkstockBrief":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":29.48,"timestamp":1787299688011,"preClose":32.06,"halted":0,"volume":24320344,"delay":0,"premium":"-67.32"},"floatMarketCap":8843000000},"requestUrl":"/m/hq/s/688185","defaultTab":"news","newsList":[{"id":"2661643602","title":"康希诺：持续规划mRNA治疗性疫苗其他管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2661643602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661643602?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:15","pubTimestamp":1787307328,"startTime":"0","endTime":"0","summary":"证券之星消息，康希诺(688185)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，贵司自研的ISL-3C-LNP三组分递送系统已与阿斯利康、盖茨基金会等建立合作，推动胶质母细胞瘤GBM治疗性疫苗及mRNA-HPV治疗性疫苗等相关管线开发，是否属实？康希诺回复：尊敬的投资人您好，对于mRNA治疗性疫苗产品，除了横纹肌肉瘤疫苗及胶质母细胞瘤疫苗，也在持续规划其他管线，后续请关注公司对于阶段性进展的相关信息披露，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264393","title":"康希诺：定期报告截止日及其后的股东人数披露，不早于当期定期报告的披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661264393?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:15","pubTimestamp":1787307327,"startTime":"0","endTime":"0","summary":"证券之星消息，康希诺08月21日在投资者关系平台上答复投资者关心的问题。顺祝健康，快乐 【比如截至到2026年8月20日贵公司的股东人数是多少?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661126439","title":"康希诺：公司早年曾就肺炎球菌结合疫苗（PCV）的相关技术与科兴控股订立一系列协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2661126439","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661126439?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:15","pubTimestamp":1787307327,"startTime":"0","endTime":"0","summary":"证券之星消息，康希诺(688185)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，科兴13价结合疫苗预计Q3申报上市，若成功获批，贵司是否有科兴13价上市销售分成？康希诺回复：尊敬的投资人您好，公司早年曾就肺炎球菌结合疫苗（PCV）的相关技术与科兴控股订立一系列协议，将按照相关约定执行，公司也会关注对方产品的开发进度。未来如产生销售收入分成，预计不会构成公司未来收入主要来源。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661758261","title":"康希诺：横纹肌肉瘤疫苗已获批IIT","url":"https://stock-news.laohu8.com/highlight/detail?id=2661758261","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661758261?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:04","pubTimestamp":1787306644,"startTime":"0","endTime":"0","summary":"证券之星消息，康希诺(688185)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，美国Moderna（莫德纳）宣布黑色素瘤皮肤癌疫苗在大型试验中达到目标影响，贵公司mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发进展如何？谢谢！！康希诺回复：尊敬的投资人您好，公司利用累积的mRNA平台技术，正在推进mRNA疫苗用于治疗横纹肌肉瘤及胶质母细胞瘤等适应症的研发工作，横纹肌肉瘤疫苗已获批IIT，脑胶质瘤疫苗处于IIT获批前阶段，同时会持续布局候选产品线。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661196259","title":"异动快报：康希诺（688185）8月21日10点46分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2661196259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661196259?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:50","pubTimestamp":1787280631,"startTime":"0","endTime":"0","summary":"证券之星8月21日盘中消息，10点46分康希诺（688185）触及涨停板。其所属行业生物制品目前下跌。领涨股为康希诺。该股为肿瘤疫苗，京津冀，疫苗概念热股，当日肿瘤疫苗概念上涨0.4%。8月20日的资金流向数据方面，主力资金净流入5029.75万元，占总成交额23.66%，游资资金净流出3443.95万元，占总成交额16.2%，散户资金净流出1585.8万元，占总成交额7.46%。近5日资金流向一览见下表：康希诺主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100015040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660547285","title":"康希诺最新公告：吸附破伤风疫苗获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2660547285","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660547285?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:31","pubTimestamp":1787221869,"startTime":"0","endTime":"0","summary":"康希诺(688185.SH)公告称，公司已获得国家药监局下发的吸附破伤风疫苗《药品注册证书》。该疫苗主要用于非新生儿破伤风预防，采用无动物源培养基进行发酵，III期临床数据显示免疫原性优于对照疫苗。公司已与远大生命科学就该疫苗达成独家商业化合作协议，授权其在大中华区进行独家推广服务。该产品上市将丰富公司商业化产品品种，拓展成人疫苗市场，对公司业绩产生积极影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000034566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660727484","title":"生物疫苗股全线大涨，康希诺等5股20CM涨停，默沙东莫德纳黑色素瘤疫苗临床试验传捷报","url":"https://stock-news.laohu8.com/highlight/detail?id=2660727484","media":"格隆汇","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660727484?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:47","pubTimestamp":1787190439,"startTime":"0","endTime":"0","summary":"8月20日，A股市场生物疫苗股全线大涨，其中，百克生物、康希诺、沃森生物、莱美药业、智飞生物20CM涨停，康华生物逼近20CM涨停，康泰生物涨超17%，华兰疫苗涨超10%，德展健康、双鹭药业、海普瑞、海欣股份、万泰生物10CM涨停，金迪克、博晖创新涨超7%，西藏药业、卫光生物、利德曼、冠昊生物、塞力医疗、赛升药业、申联生物、欧林生物涨超6%。消息面上，默沙东与莫德纳周三宣布，联合研发的黑色素瘤皮肤癌疫苗在首次晚期临床试验中取得积极初步结果。\n\n港股频道更多独家策划、专家专栏，免费查阅>>\n\n 责任编辑：栎树","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/08/20094758182842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BLSP4239.USD","688185","IE0009355771.USD","LU0689626769.HKD","LU2491050071.SGD","BK4501","LU2023250843.SGD","LU0098860793.USD","301207","LU0861579265.USD","LU0942090050.USD","LU1989772840.SGD","XLV","LU0130102774.USD","LU1571399168.USD","LU1023059063.AUD","BK0077","IE00BJJMRZ35.SGD","LU0211331839.USD","LU1989771016.USD","LU1585245621.USD","LU0868494617.USD","LU0965509283.SGD","BK4550","LU0234572021.USD","LU0965508806.USD","LU2023250504.SGD","LU1066051498.USD","SG9999001440.SGD","LU1064131003.USD","LU2125909593.SGD","LU1291159041.SGD","LU1941712348.USD","LU2361044865.SGD","IE00BN8TJ469.HKD","LU0124676726.USD","VHT","LU1061106388.HKD","FTXH","LU1037948897.HKD","BK4139","LU1066051225.USD","LGHT","LU2148510915.USD","IE00BJT1NW94.SGD","HRTS","LU0859254822.USD","IE00B2B36J28.USD","LU2361045086.USD","LU1064130708.USD","IDNA","LU0070302665.USD","RXL","BK4585","LU1430594728.SGD","LU1057294990.SGD","LU1917777945.USD","LU0965509010.AUD","BK4588","LU1093756168.USD","LU0265550359.USD","LU0006306889.USD","LU0122379950.USD","GDOC","LU1116320737.USD","BK4568","LU1069347547.HKD","BK4551","LU0320765646.SGD","LU1699723380.USD","LU2361044949.HKD","SGXZ57979304.SGD","TRUH","JDOC","LU2491050154.USD","300142","BK0196","LU0985320562.USD","LU2106854487.HKD","LU2580892862.HKD","SG9999014567.USD","LU1989772923.USD","LU2491049909.HKD","LU1934455863.HKD","FHLC","LU1116320901.HKD","300122","IE00B4R5TH58.HKD","LU2089984988.USD","MRNX","06185","SG9999014559.SGD","LU0868494708.USD","BK4533","LU1066053197.SGD","LU0823416689.USD","LU0203347892.USD","LU1328615791.USD","LU2357627491.SGD","IXJ","LU0266013472.USD","LU2125154778.USD","LU2125154935.USD","SG9999015358.SGD","LU2433249047.HKD","LU0208291251.USD","SG9999001176.SGD","LU1934455194.USD","WDNA","SG9999002232.USD","SG9999014542.SGD","LU0289739699.SGD","LU1066051811.HKD","LU2324357040.USD","688276","LU1941712264.USD","MRNA","LU0432979614.USD","LU2112291526.USD","LU0980610538.SGD","IE00BBT3K403.USD","PPH","LU0130517989.USD","PAWZ","SG9999001176.USD","BK0239","SG9999013999.USD","LU0477156953.USD","LU1035773651.USD","IE00B1BXHZ80.USD","BK4534","LU1929549753.HKD","LU1093756325.SGD","LU0648001328.SGD","SG9999002224.SGD","BK4548","IE00BSNM7G36.USD","BK4516","GNOM","IHE","LU1162221912.USD","LU1923622614.USD","BK0070","300006","LU1934455277.USD","LU2360032135.SGD","SG9999015341.SGD","IE0002141913.USD","LU0320765489.SGD","LU0203345920.USD","LU0058720904.USD","BK4559","LU0965509101.SGD","BK0188","LU1974910355.USD","LU0265550946.USD","LU2125909247.SGD","LU2580892789.USD","MRNY","LU2468319806.SGD","LU0106261372.USD","LU1983299246.USD","IE00BFTCPJ56.SGD","MRK","SG9999014575.USD","IE00BLSP4452.SGD","IYH","BK0046","BK4532","LU2461242641.AUD","LU0238689110.USD","LU1037948541.HKD","LU1201861249.SGD","IE000M9KFDE8.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660472123","title":"四大指数集体高开！生物医药板块大爆发，康希诺、沃森生物一字20CM涨停，农业、煤炭板块下跌｜开盘播报","url":"https://stock-news.laohu8.com/highlight/detail?id=2660472123","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660472123?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:38","pubTimestamp":1787189887,"startTime":"0","endTime":"0","summary":"8月20日，A股主要指数集体高开，上证指数高开0.33%，深证成指高开1.03%，创业板指高开1.27%，科创综指高开1.35%。生物医药板块爆发，创新药、ADC、基因检测、CRO方向领涨，贵金属板块表现亮眼；农业、煤炭板块表现低迷。消息面上，昨夜美股纳斯达克生物科技指数大涨6.4%，创下六年来最大涨幅；Moderna飙升176%，市值增加440亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847305243.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847305243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0077","BK4588","BK4585","BK0239","161726","BK0046","BK0070","688185","161032","159041","300142","399441","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105468","title":"破发股康希诺跌3.45% 2020年上市募52亿元中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105468","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660105468?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:29","pubTimestamp":1787041743,"startTime":"0","endTime":"0","summary":"中国经济网北京8月18日讯 康希诺 今日收报55.94元，跌幅3.45%。该股目前处于破发状态。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海证券。 康希诺首次公开发行股票发行费用为2.21亿元，其中，保荐及承销费用2.05亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260818/32338525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","LU2580892789.USD","LU2148510915.USD","LU0405327494.USD","LU1781817850.SGD","BK0196","LU1580142542.USD","LU2495084118.USD","LU2289578879.USD","BK0012","LU1794554557.SGD","LU1997245094.SGD","688185","BK0183","600030","LU1720050803.USD","LU1255011170.USD","BK1147","BK0276","LU0405327148.USD","LU1997244956.HKD","BK1516","LU1064130708.USD","LU1997245177.USD","06030","BK1564","LU1064131003.USD","LU1328615791.USD","LU2580892862.HKD","BK0028","BK0239","LU1655091616.SGD","IPOS","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660170760","title":"股市必读：康希诺新发布《康希诺H股公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660170760","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660170760?lang=zh_cn&edition=full","pubTime":"2026-08-17 02:49","pubTimestamp":1786906151,"startTime":"0","endTime":"0","summary":"公司公告汇总康希诺H股公告康希诺生物股份公司董事会宣布将于2026年8月27日举行董事会会议，主要议程包括审议及批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布，并考虑建议派发中期股息（如有）。自愿披露关于吸附无细胞百（五组分）白破联合疫苗药品注册申请获得受理的公告康希诺生物股份公司研发的吸附无细胞百（五组分）白破联合疫苗药品注册申请已获国家药品监督管理局受理，受理号为CXSS2600123。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700001041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659932174","title":"康希诺：青少年及成人用百白破疫苗药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2659932174","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659932174?lang=zh_cn&edition=full","pubTime":"2026-08-16 15:36","pubTimestamp":1786865770,"startTime":"0","endTime":"0","summary":"8月16日，康希诺公告称，公司研发的吸附无细胞百(五组分)白破联合疫苗(6岁及以上人群用)境内生产药品注册上市许可申请近日获国家药监局受理。该产品适用于6岁及以上人群，为青少年及成人的百白破加强疫苗，国内暂无获批同类产品，若成功上市将填补市场空白。该产品已纳入优先审评品种，后续还需经过技术审评、临床试验现场核查等程序，获批上市销售将对公司经营业绩产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608163842500828.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608163842500828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659176575","title":"每周股票复盘：康希诺（688185）将审议中期业绩及股息","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176575?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:55","pubTimestamp":1786820113,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，康希诺报收于56.29元，较上周的54.27元上涨3.72%。本周，康希诺8月13日盘中最高价报58.28元。本周关注点公司公告汇总：康希诺将于2026年8月27日召开董事会，审议中期业绩及派发中期股息事宜。公司公告汇总康希诺生物股份公司董事会宣布将于2026年8月27日举行董事会会议，主要议程包括审议及批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布，并考虑建议派发中期股息（如有）。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659140885","title":"康希诺（688185）披露2026年中期业绩审议安排，8月14日股价下跌0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659140885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659140885?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:30","pubTimestamp":1786717849,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，康希诺报收于56.29元，较前一交易日下跌0.76%，最新总市值为139.06亿元。该股当日开盘56.47元，最高57.2元，最低55.27元，成交额达1.24亿元，换手率为1.93%。近日，康希诺生物股份公司董事会宣布将于2026年8月27日举行董事会会议，主要议程包括审议及批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布，并考虑建议派发中期股息（如有）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400040624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659321138","title":"生物制品概念强势拉升，康希诺婴幼儿百白破联合疫苗正式启动市场供应丨异动情报","url":"https://stock-news.laohu8.com/highlight/detail?id=2659321138","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659321138?lang=zh_cn&edition=full","pubTime":"2026-08-13 12:17","pubTimestamp":1786594620,"startTime":"0","endTime":"0","summary":"南方财经8月13日电，8月13日，生物制品盘中上涨3.01%，相关成分股中，近岸蛋白（688137）上涨13.99%，舒泰神（300204）上涨11.12%，百普赛斯（301080）上涨9.03%，奥浦迈（688293）上涨8.78%，君实生物（688180）上涨8.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133840271458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133840271458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658495675","title":"每周股票复盘：康希诺（688185）H股及A股股本无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2658495675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658495675?lang=zh_cn&edition=full","pubTime":"2026-08-09 03:13","pubTimestamp":1786216391,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，康希诺报收于54.27元，较上周的50.19元上涨8.13%。本周，康希诺8月7日盘中最高价报54.49元。康希诺当前最新总市值134.07亿元，在生物制品板块市值排名20/51，在两市A股市值排名1411/5205。H股总数为132,670,900股，于香港联交所上市；A股总数为114,372,901股，在上交所科创板上市。股份期权计划方面，2025年核心管理层H股购股权计划项下有860,000份期权，本月无行使或变动。2025年A股限制性股票激励计划涉及2,054,600股，本月未新增发行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900001098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399300","BK0239","688185","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657252403","title":"股市必读：康希诺新发布《康希诺H股公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657252403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657252403?lang=zh_cn&edition=full","pubTime":"2026-08-06 02:42","pubTimestamp":1785955333,"startTime":"0","endTime":"0","summary":"公司公告汇总康希诺H股公告截至2026年7月31日，康希诺H股总数为132,670,900股，于香港联交所上市；A股总数为1,114,372,901股，在上交所科创板上市；法定注册资本及已发行股份均无变动；库存股数量为零；H股类别公众持股量符合《上市规则》规定的5%最低要求；2025年核心管理层H股购股权计划项下存续期权860,000份，本月无行使或变动；2025年A股限制性股票激励计划涉及2,054,600股，本月未新增发行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600002065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654575330","title":"每周股票复盘：康希诺（688185）脑膜炎疫苗拟扩龄至17岁","url":"https://stock-news.laohu8.com/highlight/detail?id=2654575330","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654575330?lang=zh_cn&edition=full","pubTime":"2026-07-26 02:19","pubTimestamp":1785003548,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，康希诺报收于48.35元，较上周的49.55元下跌2.42%。本周，康希诺7月22日盘中最高价报51.98元。本周关注点公司公告汇总：ACYW135群脑膜炎球菌疫苗拟将适用人群扩大至3月龄~17周岁。公司公告汇总康希诺生物股份公司公告，其ACYW135群脑膜炎球菌多糖结合疫苗（曼海欣）药品补充申请已获国家药品监督管理局受理，受理号为CYSB2600211。本次补充申请拟将曼海欣的适用人群年龄范围由“3月龄~6周岁儿童”扩大至“3月龄~17周岁人群”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652425969","title":"康希诺(688185.SH)：ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)药品补充申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2652425969","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652425969?lang=zh_cn&edition=full","pubTime":"2026-07-19 16:41","pubTimestamp":1784450464,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺 发布公告，公司的ACYW135群脑膜炎球菌多糖结合疫苗药品补充申请于近日获得国家药品监督管理局出具的《受理通知书》，受理号：CYSB2600211。本次补充申请为曼海欣的适用人群年龄范围由“3月龄~6周岁儿童”扩大至“3月龄~17周岁人群”。曼海欣凭借其创新优势，展现出强劲的市场表现力，实现了市场占有率的不断攀升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469410.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺(688185.SH)：ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)药品补充申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","159646","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652911405","title":"7月17日康希诺跌6.42%，广发科创板两年定开混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652911405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652911405?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:23","pubTimestamp":1784276625,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日康希诺跌6.42%，收盘报49.55元，换手率2.26%，成交量2.58万手，成交额1.31亿元。重仓康希诺的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发科创板两年定开混合。广发科创板两年定开混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700029735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649692485","title":"每周股票复盘：康希诺（688185）H股及A股股本无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2649692485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649692485?lang=zh_cn&edition=full","pubTime":"2026-07-05 04:12","pubTimestamp":1783195933,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，康希诺报收于53.05元，较上周的47.9元上涨10.75%。H股总数为132,670,900股，于香港联交所上市；A股总数为1114,372,901股，在上海证券交易所科创板上市。股份期权计划方面，2025年核心管理层H股购股权计划项下存续的股份期权为860,000股，本月无新增或注销。2025年A股限制性股票激励计划项下，首次授予的2,054,600股限制性股票状态维持不变。公司确认H股类别已满足公众持股量要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500001481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","159982","399300","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787314464060,"stockEarnings":[{"period":"1week","weight":0.1359},{"period":"1month","weight":0.2847},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.0083},{"period":"1year","weight":-0.2236},{"period":"ytd","weight":0.0251}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0365},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康希诺生物股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"16477人(较上一季度增加Infinity%)","perCapita":"6941股","listingDate":"2020-08-13","address":"天津市东丽区经济技术开发区西区南大街185号西区生物医药园四层401-420","registeredCapital":"24704万元","survey":" 康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是疫苗销售、药品生产工艺研究开发业务、技术转移及中间品销售。公司自主研发的“多糖蛋白结合疫苗关键技术及产业化”项目荣获天津市科学技术进步一等奖。","listedPrice":209.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺,688185,康希诺股票,康希诺股票老虎,康希诺股票老虎国际,康希诺行情,康希诺股票行情,康希诺股价,康希诺股市,康希诺股票价格,康希诺股票交易,康希诺股票购买,康希诺股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}